| scholarly article | Q13442814 |
| P50 | author | Thomas E Ahlering | Q46075903 |
| Frank L. Meyskens, Jr. | Q22006852 | ||
| Hoda Anton-Culver | Q28052887 | ||
| Argyrios Ziogas | Q30831638 | ||
| P2093 | author name string | Christine E McLaren | |
| Eugene W Gerner | |||
| Ronald Lieberman | |||
| Thomas E Ahlering | |||
| Ray Nagle | |||
| Anne R Simoneau | |||
| Sharon Fujikawa-Brooks | |||
| Hagit Yerushalmi | |||
| P2860 | cites work | Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial | Q45062085 |
| The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation | Q45169840 | ||
| Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. | Q45238922 | ||
| Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps | Q46301309 | ||
| Differences in ornithine decarboxylase and androgen receptor allele frequencies among ethnic groups | Q46672639 | ||
| A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. | Q50503298 | ||
| Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine. | Q53471823 | ||
| Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. | Q53479543 | ||
| Cell transformation, invasion, and angiogenesis: a regulatory role for ornithine decarboxylase and polyamines? | Q53753522 | ||
| Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. | Q54032299 | ||
| Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine | Q54277312 | ||
| SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. | Q55035197 | ||
| Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display | Q63966054 | ||
| High-performance liquid chromatographic procedure for the simultaneous determination of the natural polyamines and their monoacetyl derivatives | Q70730581 | ||
| Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine | Q71621379 | ||
| The development of human benign prostatic hyperplasia with age | Q72743475 | ||
| Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice | Q73034159 | ||
| Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine | Q73355841 | ||
| Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer | Q79776932 | ||
| Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy | Q81280205 | ||
| Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer | Q81476462 | ||
| A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene | Q28194213 | ||
| Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene | Q28196474 | ||
| Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention | Q28200776 | ||
| Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme | Q31861401 | ||
| Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas | Q33346905 | ||
| Inhibition of tumor promotion by DL-alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase | Q33392926 | ||
| Polyamines and cancer: old molecules, new understanding | Q34362757 | ||
| The influence of finasteride on the development of prostate cancer | Q34534815 | ||
| The ageing male: demographics and challenges | Q34712021 | ||
| Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment | Q35645345 | ||
| Polyamines as clinical laboratory tools | Q35776575 | ||
| Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention | Q36775315 | ||
| Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases | Q36803757 | ||
| Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges | Q39377735 | ||
| Altered polyamine profiles in prostatic hyperplasia and in kidney tumors | Q39496435 | ||
| Polyamines in normal and cancer cells | Q39597954 | ||
| Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials | Q40939818 | ||
| Effect of α-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues | Q41512785 | ||
| Polyamines in the male reproductive system. | Q41530814 | ||
| Effects of α-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on testosterone-induced regeneration of prostate and seminal vesicle in castrated rats | Q42065740 | ||
| Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial | Q43514966 | ||
| Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions | Q43603023 | ||
| Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. | Q43860642 | ||
| A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers | Q44175750 | ||
| Chemoprevention of prostate carcinogenesis by DFMO and/or finasteride treatment in male Wistar rats. | Q44322483 | ||
| Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival | Q44407580 | ||
| Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk | Q44721022 | ||
| Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention | Q44788424 | ||
| Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice | Q44976886 | ||
| P433 | issue | 2 | |
| P921 | main subject | placebo | Q269829 |
| P304 | page(s) | 292-299 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Cancer Epidemiology, Biomarkers & Prevention | Q326334 |
| P1476 | title | The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial | |
| P478 | volume | 17 |
| Q36457059 | A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity |
| Q33608811 | A profusion of upstream open reading frame mechanisms in polyamine-responsive translational regulation. |
| Q51135191 | Anticarcinogenic activity of alpha-difluoromethylornithine, ginseng, eleutherococcus, and leuzea on radiation-induced carcinogenesis in female rats. |
| Q37403674 | Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival |
| Q37681944 | Cancer chemoprevention locks onto a new polyamine metabolic target |
| Q35595617 | Cellular diamine levels in cancer chemoprevention: modulation by ibuprofen and membrane plasmalogens |
| Q26471702 | Chemoprevention agents for prostate cancer |
| Q64997513 | Coxsackievirus B3 Responds to Polyamine Depletion via Enhancement of 2A and 3C Protease Activity. |
| Q36838564 | Current status of the polyamine research field |
| Q35583635 | DFMO: targeted risk reduction therapy for colorectal neoplasia |
| Q37679982 | Design of polyamine-based therapeutic agents: new targets and new directions |
| Q34763431 | Diagnosis of prostate cancer using differentially expressed genes in stroma |
| Q38765477 | Difluoromethylornithine in cancer: new advances |
| Q33859016 | Difluoromethylornithine: the proof is in the polyamines |
| Q33883491 | Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase |
| Q39838831 | Divergent regulation of the key enzymes of polyamine metabolism by chiral alpha-methylated polyamine analogues. |
| Q39935779 | Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma |
| Q35027354 | Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling |
| Q37570555 | Emerging drugs for prostate cancer |
| Q37543114 | Enhanced evaluation of selective androgen receptor modulators in vivo. |
| Q38957285 | Epibrassinolide-induced apoptosis regardless of p53 expression via activating polyamine catabolic machinery, a common target for androgen sensitive and insensitive prostate cancer cells |
| Q39844175 | Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. |
| Q39498622 | Inducible expression of antizyme 1 in prostate cancer cell lines after lentivirus mediated gene transfer |
| Q26740548 | One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling |
| Q38738879 | Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling |
| Q46636207 | Ornithine decarboxylase as a therapeutic target for endometrial cancer |
| Q63681549 | PGC-1α inhibits polyamine synthesis to suppress prostate cancer aggressiveness |
| Q91675188 | Polyamine Depletion Inhibits Bunyavirus Infection via Generation of Noninfectious Interfering Virions |
| Q41107342 | Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. |
| Q26864516 | Polyamines and cancer: implications for chemotherapy and chemoprevention |
| Q38315056 | Polyamines are oncometabolites that regulate the LIN28/let-7 pathway in colorectal cancer cells |
| Q38257840 | Polyamines metabolism and breast cancer: state of the art and perspectives |
| Q34371057 | Prevention and early detection of prostate cancer |
| Q37522449 | Recent advances in the development of polyamine analogues as antitumor agents |
| Q36958356 | Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice |
| Q30484125 | Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine |
| Q38474358 | Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma |
| Q36653461 | Targeting polyamines and inflammation for cancer prevention |
| Q33761692 | The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification |
Search more.